Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.1bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥2.3bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥1.1bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥84m2024-04-01 → 2024-09-30Cons.Operating income
Operating income−¥116m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥78m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income−¥168m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥114m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥79m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax−¥101m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥82m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥176m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥104m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥82m2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥104m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥2.1bnat 2024-09-30Cons.Assets
Total assets¥1.7bnat 2024-03-31Cons.Assets
Total assets¥1.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥694mat 2024-09-30Cons.Liabilities
Total liabilities¥477mat 2024-03-31Cons.Liabilities
Net assets / equity¥1.4bnat 2024-09-30Cons.Net assets
Net assets / equity¥1.2bnat 2024-03-31Cons.Net assets
Net assets / equity¥1.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥190mat 2024-09-30Cons.Cash and deposits
Cash and deposits¥297mat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥190mat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥297mat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥238mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥173mat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥248m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥77m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥54m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥432m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥87m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥6m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥573m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥288m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥126m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-1.382024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.312023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-22023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio65.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio71.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio72.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 32
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥59m
jpcrp040300-q2r_E05674-000Beauty And Wellness Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥500m
jpcrp040300-q2r_E05674-000Beauty And Wellness Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥500m
jpcrp040300-q2r_E05674-000Beauty And Wellness Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥10m
jpcrp040300-q2r_E05674-000Cosmetics Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥439m
jpcrp040300-q2r_E05674-000Cosmetics Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥439m
jpcrp040300-q2r_E05674-000Cosmetics Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥2m
jpcrp040300-q2r_E05674-000Regenerative Medicine Related Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥181m
jpcrp040300-q2r_E05674-000Regenerative Medicine Related Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥181m
jpcrp040300-q2r_E05674-000Regenerative Medicine Related Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥9m
jpcrp040300-q2r_E05674-000Sustainable Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05674-000Sustainable Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05674-000Sustainable Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥29m
—segment totalrevenue2024-04-01 → 2024-09-30¥1.1bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥1.1bn
—segment totalsegment profit2024-04-01 → 2024-09-30−¥26m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥40m
jpcrp040300-q2r_E05674-000Beauty And Wellness Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥538m
jpcrp040300-q2r_E05674-000Beauty And Wellness Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥538m
jpcrp040300-q2r_E05674-000Beauty And Wellness Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥16m
jpcrp040300-q2r_E05674-000Cosmetics Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥395m
jpcrp040300-q2r_E05674-000Cosmetics Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥395m
jpcrp040300-q2r_E05674-000Cosmetics Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥56m
jpcrp040300-q2r_E05674-000Regenerative Medicine Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥168m
jpcrp040300-q2r_E05674-000Regenerative Medicine Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥168m
jpcrp040300-q2r_E05674-000Regenerative Medicine Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E05674-000Sustainable Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05674-000Sustainable Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05674-000Sustainable Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥37m
—segment totalrevenue2023-04-01 → 2023-09-30¥1.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥1.1bn
—segment totalsegment profit2023-04-01 → 2023-09-30−¥76m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 489
ItemContextValueUnit
Other clPrior1YearInstant48001000JPY
Other clCurrentQuarterInstant55011000JPY
Current liabilitiesPrior1YearInstant455897000JPY
Current liabilitiesCurrentQuarterInstant672786000JPY
Asset retirement obligations nclPrior1YearInstant15580000JPY
Asset retirement obligations nclCurrentQuarterInstant15652000JPY
Other nclPrior1YearInstant5543000JPY
Other nclCurrentQuarterInstant5512000JPY
Noncurrent liabilitiesPrior1YearInstant21123000JPY
Noncurrent liabilitiesCurrentQuarterInstant21165000JPY
LiabilitiesPrior1YearInstant477021000JPY
LiabilitiesCurrentQuarterInstant693952000JPY
Capital stockPrior1YearInstant1134606000JPY
Capital stockCurrentQuarterInstant1256386000JPY
Capital surplusPrior1YearInstant2090726000JPY
Capital surplusCurrentQuarterInstant2212506000JPY
Retained earningsPrior1YearInstant-2031404000JPY
Retained earningsCurrentQuarterInstant-2112953000JPY
Shareholders equityPrior1YearInstant1193928000JPY
Shareholders equityCurrentQuarterInstant1355940000JPY
Subscription rights to sharesPrior1YearInstant6707000JPY
Subscription rights to sharesCurrentQuarterInstant6524000JPY
Net assetsPrior1YearInstant1200635000JPY
Net assetsCurrentQuarterInstant1362464000JPY
Liabilities and net assetsPrior1YearInstant1677657000JPY
Liabilities and net assetsCurrentQuarterInstant2056416000JPY
Net salesPrior1YTDDuration1105111000JPY
Net salesCurrentYTDDuration1123910000JPY
Cost of salesPrior1YTDDuration565266000JPY
Cost of salesCurrentYTDDuration535153000JPY
Gross profitPrior1YTDDuration539845000JPY
Gross profitCurrentYTDDuration588757000JPY
Selling general and administrative expensesPrior1YTDDuration655737000JPY
Selling general and administrative expensesCurrentYTDDuration672867000JPY
Operating incomePrior1YTDDuration-115891000JPY
Operating incomeCurrentYTDDuration-84109000JPY
Interest income noiPrior1YTDDuration1000JPY
Interest income noiCurrentYTDDuration16000JPY
Subsidy income noi bountyPrior1YTDDuration565000JPY
Subsidy income noi bountyCurrentYTDDuration4996000JPY
Other noiPrior1YTDDuration1793000JPY
Other noiCurrentYTDDuration3040000JPY
Non operating incomePrior1YTDDuration2360000JPY
Non operating incomeCurrentYTDDuration8053000JPY
Interest expenses noePrior1YTDDuration-JPY
Interest expenses noeCurrentYTDDuration1211000JPY
Foreign exchange losses noePrior1YTDDuration8000JPY
Foreign exchange losses noeCurrentYTDDuration2000JPY
Stock issuance cost noePrior1YTDDuration190000JPY
Stock issuance cost noeCurrentYTDDuration562000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass